Tests stereotactic body radiation for colorectal cancer that has spread to the liver
Tests focused radiation on a few liver tumors in adults with colorectal cancer.
Plain-language title generated from the registry record
Registry title: SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
Key facts
- Where
- Edmonton, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Cross Cancer InstituteEdmonton, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AHS Cancer Control Alberta
- Trial code
- NCT05775146
- Record updated
- 28 October 2026
- Original description
The purpose of this study is to prospectively evaluate the feasibility of SBRT for the management of synchronous oligo metastatic liver metastases from colorectal cancers.Read full original descriptionShow less
Phase II Single Arm Feasibility Trial to Evaluate Stereotactic Ablative Radiation of Metastases for the Management of Colorectal Cancer With Synchronous Oligo-metastases in Liver
The purpose of this study is to prospectively evaluate the feasibility of SBRT for the management of synchronous oligo metastatic liver metastases from colorectal cancers.
Inclusion: Age ≥ 18 years; ECOG (Eastern Cooperative Oncology Group) 0-2; Able to provide written informed consent; 1-5 Liver lesions with max size of ≤5cm for a single lesion and restricted to one lobe of liver; deemed at Multi-Disciplinary Tumor Board (MDT) to be potentially amenable for SBRT with curative intent; Liver lesion identified within 3 months of diagnosis of primary and deemed at Multi-Disciplinary Tumor Board (MDT) to be potentially amenable for SBRT with curative intent; Plan for resection of primary with curative intent; Patients with liver metastases and potentially resectable/ablatable lung mets can be included; Colon cancer patients who have undergone upfront resection of primary colonic lesion can be included; Able and willing to comply with the terms of the protocol including health-related quality of life (HRQoL) questionnaires; Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40 mIU/mL to confirm menopause; Females must not be breastfeeding; Male patients should agree to not donate sperm during the study.
Exclusion: Not a suitable candidate for liver resection surgery; Patients who have undergone previous surgery or ablation for liver lesions; Planned simultaneous resection of primary and liver metastases; Past history of cancer within 5 years (except basal cell carcinoma); Extra-hepatic metastases (except potentially resectable lung mets); Not a suitable candidate for SBRT; Pregnancy; Patients with Child-Pugh C and documented cirrhosis.